Praxis Precision Medicines, Inc. (PRAX) Form 8-K — Nov 9, 2026
Praxis Precision Medicines reported a Q3 2026 net loss of $94.2 million ($3.23 per share), widening from $73.9 million a year ago, driven largely by a jump in G&A expenses to $42.7 million from $12.6 million as it builds commercial infrastructure for two upcoming launches. The company holds $1.3 billion in cash and marketable securities, up $359.9 million from year-end 2025 after its January 2026 follow-on offering, providing runway into 2028. Two PDUFA dates are imminent: an FDA decision on relutrigine for SCN2A/SCN8A DEEs by December 27, 2026, and on ulixacaltamide for essential tremor by January 29, 2027, with topline EMERALD study data in broad DEEs expected in Q4 2026.
Key figures
- Revenue
- 0
- Total Assets
- 1312073000
- Cash Position
- 1300000000
- Shares Outstanding
- 27900000
- Cash runway
- into 2028
- Cash dec 31 2025
- 926100000
- Cash increase qtd
- 359900000
- Pdufa relutrigine
- 2026-12-27
- Q3 2025 ga expense
- 12562000
- Q3 2025 rd expense
- 65797000
- Q3 2026 ga expense
- 42709000
- Q3 2026 rd expense
- 64205000
- Pdufa ulixacaltamide
- 2027-01-29
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.